You are here: Industry Insights > neurodegenerative diseases

News List

Sanofi pays Denali $125M to buy into RIPK1 program 2. Biotech Sanofi pays Denali $125M to buy into RIPK1 program fiercebiotech
November 02, 2018
Sanofi is paying $125 million (€110 million) upfront for a stake in two RIPK1 inhibitors in development at Denali. The agreement covers small molecules designed to treat multiple...
Biohaven picks up AstraZeneca CNS drug, plans phase 3 fiercebiotech
September 06, 2018
Biohaven Pharmaceutical has licensed an experimental treatment of the neurodegenerative disorder multiple system atrophy (MSA) from AstraZeneca.
How tau disrupts brain-cell connections in Alzheimer’s disease fiercebiotech
September 06, 2018
Scientists found a new mechanism in Alzheimer's where an abnormal form of tau disrupts nuclear pore complex that handles molecular transport between nucleus and cytoplasm. (Colin Behrens)
AC Immune finds new antibodies targeting neurodegenerative diseases pharmaceutical-technology
August 24, 2017
Swiss clinical stage biopharmaceutical company AC Immune has discovered new antibodies against two targets, Alpha-synuclein and TDP-43, in the pathogenesis of neurodegenerative diseases.
Lilly-backed Cavion poaches Teva executive as R&D head fiercebiotech
August 16, 2017
Cavion got off a $26.1 million series A financing this year with Lilly Ventures, Novartis Venture Fund and Enso Ventures.
Charles River doubles down on CNS research with Brains On-Line buy fiercebiotech
August 10, 2017
Charles River acquires Brains On-Line for €18 million, enhancing its position as a single-source provider for a broad portfolio of CNS discovery services.
AC Immune and Essex to develop biological treatment for neurodegenerative diseases pharmaceutical-technology
May 27, 2017
AC Immune and Essex Bio-Technology have signed a research collaboration agreement to conduct a pre-clinical study and clinical codevelopment of a novel biological therapeutic to treat neurodegenerative diseases and neuroinflammation.
Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor b3cnewswire
April 07, 2017
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia
Cypralis to develop new cyclophilin inhibitors for neurodegenerative diseases pharmaceutical-technology
March 03, 2017
UK-based life sciences company Cypralis has secured funding from the Alzheimer’s Drug Discovery...

Previous page 1 2 Next page